Pharmacokinetic of Arsenic Trioxide in Newly Diagnosed Acute Promyelocytic Leukemia Patients
The high complete remission rate with arsenic trioxide (ATO) in relapsed Acute Promyelocytic Leukemia (APL) patients has been led to its use in newly diagnosed patients. Twenty newly diagnosed APL patients between January 2006 and 2007 received 2 h intravenous infusion of 10 mg day super(-1) arsenic...
Saved in:
| Published in: | Journal of applied sciences (Asian Network for Scientific Information) Vol. 8; no. 24; pp. 4617 - 4623 |
|---|---|
| Main Authors: | , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
15-12-2008
|
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The high complete remission rate with arsenic trioxide (ATO) in relapsed Acute Promyelocytic Leukemia (APL) patients has been led to its use in newly diagnosed patients. Twenty newly diagnosed APL patients between January 2006 and 2007 received 2 h intravenous infusion of 10 mg day super(-1) arsenic trioxide for induction therapy until achieving complete remission. Plasma arsenic concentration was analyzed by graphite furnace atomic absorption method by dilution of plasma with a suitable matrix modifier. The concentration of arsenic in 24 h urine of patients was measured by using a valid standard addition method and a suitable matrix modifier. The Limits of Detection (LOD) were 1.2 and 1.5 mu g L super(-1) for arsenic in plasma and urine, respectively. Pharmacokinetic parameters of 20 patients were as following: C sub(max): 43.6 plus or minus 19.5 mu gL super(-1), t sub(max):2.15 plus or minus 0.7 h, AUC sub(0-24): 683 plus or minus 317 mu g h L super(-1), AUC sub(0- infinity ): 2027 plus or minus 958 mu g h L super(-1), t sub(1/2) 41 plus or minus 10 h, k sub(el): 0.02 plus or minus 0.01 h super(-1), V sub(d): 5.6 plus or minus 3.6 L kg super(-1) and CI sub(totol): 0.1 plus or minus 0.05 L kg super(-1) h super(-1). During the first day of induction, 1.4 plus or minus 0.2% of administrated arsenic excreted into urine. Renal clearance was 5.1 plus or minus 4.1 mL kg super(-1) h super(-1). However, the results showed that the pharmacokinetic of ATO in newly diagnosed APL patients weren't dependent to the sex of patients. |
|---|---|
| Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ISSN: | 1812-5654 |
| DOI: | 10.3923/jas.2008.4617.4623 |